Efficacy News and Research

RSS
Medicinewise News' edition examines latest evidence for determining absolute CVD risk, treatment options

Medicinewise News' edition examines latest evidence for determining absolute CVD risk, treatment options

Viewpoints: Decoupling jobs and insurance; overblown fear: Medicaid willl take my house

Viewpoints: Decoupling jobs and insurance; overblown fear: Medicaid willl take my house

Topiramate reduces drinking in patients committed to abstinence from alcohol

Topiramate reduces drinking in patients committed to abstinence from alcohol

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

CHOP develops unique laboratory test to characterize genes that encode HLA molecules

CHOP develops unique laboratory test to characterize genes that encode HLA molecules

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen launches Inflectra into Central and Eastern Europe

Cogstate technology to be applied in paediatric clinical trial in the U.S.

Cogstate technology to be applied in paediatric clinical trial in the U.S.

Study provides first empirical evidence that foreign aid can greatly improve foreign public opinion

Study provides first empirical evidence that foreign aid can greatly improve foreign public opinion

MIT develops robot that may speed up drug development for stroke patients

MIT develops robot that may speed up drug development for stroke patients

Study shows dye brilliant blue G may improve recovery from traumatic brain injuries

Study shows dye brilliant blue G may improve recovery from traumatic brain injuries

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Gilead submits NDA  to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

NASA signs patent to develop novel biotechnology approaches that could have medical applications

NASA signs patent to develop novel biotechnology approaches that could have medical applications

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

Ipsen’s phase III clinical trial evaluating Decapeptyl in patients with prostate cancer meets primary endpoints

pSivida announces financial results for second quarter 2014

pSivida announces financial results for second quarter 2014

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.